Reproducibility of forced inspiratory and expiratory volumes after bronchodilation in patients with COPD or asthma  by TAUBE, C et al.
Vol.97 (2002) 568^577Reproducibility of forced inspiratory and expiratory
volumes after bronchodilation in patients with
COPD or asthma
C.TAUBE*w, F.KANNIESS*, L.GROº NKE*, K.RICHTER*,M.MUº CKE*, K. PAASCH,G.EICHLER*,
R. A. JOº RRES* ANDH.MAGNUSSEN*
*Pulmonary Research Institute,Hospital Grohansdorf,Center for Pneumology and Thoracic Surgery,Grohansdorf,
Germany, zDepartment of Medical Science, Boehringer Ingelheim Pharma KG, Ingelheim,Germany
Abstract The aimofthepresent studywas to assess thereproducibilityofchangesin forcedinspiratory volumes after
bronchodilator inhalation.Thirteen patients with chronic obstructive pulmonary disease (COPD) (FEV1, 32^75%pred)
and 10 patients with asthma (FEV1, 43^75%pred) inhaled either 200 mg fenoterol or 200 mg oxitropium bromide or
placebo, each of them on three occasions, on nine different days in a randomised, cross-over, double-blind fashion.
Forced expiratory (FEV1) and inspiratory (FIV1) volumes were measured before and 30min after inhalation. In patients
with COPD, the increase in FEV1 (coefficientof variation) was 221ml (43%) after fenoterol and 235ml (33%) afteroxitro-
pium; changes in FIV1 were 301ml (45%) and 360ml (29%). In patients with asthma, FEV1 improved by 618ml (26%)
and 482ml (25%), FIV1 by 553ml (41%) and 475ml (23%). In less severe COPD or asthma, the reduction in dyspnoea
was associated with the improvements in both FIV1 and FEV1, but in severe COPD with the improvement in FIV1 only.
The datademonstratethat, at least intermsofrelative changes, thereproducibilityof bronchodilatorresponsesinterms
of FIV1is similar to thatof FEV1and they underline the assertion of FIV1being a sensible parameter particularly in severe
COPD.r2002 Elsevier Science Ltd.Allrights reserved.
doi:10.1053/rmed.2001.1411, available online athttp://www.sciencedirect.com
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Chronic obstructive pulmonary disease (COPD) is con-
ventionally characterised by progressive development of
air£ow obstruction that is not fully reversible upon inha-
lation of bronchodilators (1).The destruction of lung par-
enchyma related to bronchitis and emphysema (2) is
associated with a loss of lung and airway elasticity (3,4)
that favours expiratory airway collapse and £ow limita-
tion, asmajor characteristics of the disease (5,6).
Based on this one might hypothesise that by the
occurrence of airway collapse the e¡ects of broncho-Received 21September 2001; accepted in revised form 27 May 2002.
Correspondence should be addressed to: Helgo Magnussen,MD,
Hospital Grohansdorf,Center for Pneumology and Thoracic Surgery,
W˛hrendamm80,D-22927Grohansdorf,Germany.Fax: +49 4102 601
245 E-mail: magnussen@pulmoresearch.de
wCurrent address: Division of Cell Biology,Department of Pediatrics,
National Jewish Medical and Research Center,1400 Jackson Street,
Denver,CO 80206,U.S.A.
This study was funded by Boehringer-Ingelheim Pharma KG,D-55216
Ingelheim,Germany.dilators are underestimated or even missed, when
assessed through conventional forced expiratory man-
oeuvres. Indeed we found the e¡ect of an inhaled b2-
adrenoceptor agonist to be more pronounced during
forced inspiration than expiration in COPD (7). In addi-
tion, it was the improvement in forced inspiration, parti-
cularly that in FIV1, and not that in forced expiration
(8,9), which correlated with the reduction in dyspnoea.
From thiswe concluded that the assessmentof broncho-
dilation by forced inspiration is a promising tool in pa-
tients with COPD.
However, the clinical usefulness of these measure-
ments obviously depends on their reproducibility. Such
information is available for FEV1but not for FIV1.Thedata
obtained for FEV1 indicated coe⁄cients of variation
(SD/mean) ranging between 46 and 67% (10,11) in COPD
and slightly lower values of 34^50% in asthma (11). Con-
sequently, it was the aim of the present study to assess
the reproducibility of bronchodilator responses in terms
of forced inspiratory parameters, both in patients with
COPD and in patients with asthma. To be independent
REPRODUCIBILITYOFFIV1 569of the speci¢c mechanism of bronchodilation, responses
were measured after inhalation of equipotent doses of
fenoterol and oxitropium bromide and compared to pla-
cebo.
MATERIALANDMETHODS
Patients
Ten patients with the diagnosis of asthma (12) and13 pa-
tients with the diagnosis of COPD (1) completed the
study. Patients ful¢lled all of the criteria required in the
guidelines, showing FEV175%pred, andwere in a stable
clinical condition for at least 6 months. All patients with
asthma took b2-adrenoceptor agonists, eight inhaled
corticosteroids, two systemic steroids in constant dose,
and one a leukotriene-receptor antagonist. All patients
with COPD inhaled b2-adrenoceptor agonists and antic-
holinergics, six inhaled corticosteroids, and ¢ve took
theophylline.The study was approvedby the local ethics
committee and patients gave their written informed
consent.
Study protocol
The protocol included one screening and nine study vis-
its.On the screening visit, medical history and examina-
tion was performed, and lung function, transfer factor
for carbon monoxide (TLCO), inspiratory pressure after
0.1s (P0.1) and maximal inspiratory pressure (PImax ) were
determined. In addition, a sputum induction was per-
formed to obtain cell di¡erentials and the concentration
of exhaled NOwasmeasured at a constant £ow rate.
Inspiratory vital capacity (IVC), expiratory (SRawex)
and inspiratory (SRawin) speci¢c airway resistance, total
lung capacity (TLC), intra-thoracic gas volume (ITGV),
residual volume (RV), and inspiratory capacity (IC) were
determined using a body plethysmograph (Masterlab,
Jaeger, Wˇrzburg, Germany) (13). To assess FEV1, FVC,
PEF, PIF and FIV1, forced expiratory and inspiratoryman-
oeuvres were performed as described previously (7) fol-
lowing the appropriate standards (14). TLCO was
determined by the single breath method (15). P0.1 was
measured as pressure 100ms after the start of inspira-
tion during tidal breathing (mean of 10 trials), Pimax
through maximal inspiratory e¡ort over 1s against a
closed shutter, the highest value from two acceptable
manoeuvres being chosen.
Study visits were separated by 1^5 days and started
3 days after the screening visit. Inhaled short-acting
bronchodilators were withheld for 6h and long-acting
for 12, whereas other medications were not changed
throughout the study. Patients underwent lung function
testing in the morning, in sitting position, including P0.1
and Pimax. Then patients inhaled either 200mg fenoterol,
200mg oxitropium bromide, or placebo throughmetred-dose inhalers with an inhalation chamber. Each
medicationwas given on three di¡erent days, in a rando-
mised, cross-over, double-blind fashion. Thirty minutes
after inhalation the change in theperception of dyspnoea
was assessed through the visual analog scale (VAS) (7,16)
and lung function, P0.1, and Pimax weremeasured again.
TheVASusedwas a 20 cmlonghorizontal line, labelled
‘‘verymuchworse’’ at the left end,‘‘verymuchbetter’’on
the right and ‘‘no change’’ in the middle (7,9,17). Ratings
were expressed as percentage length, ranging from
100% (‘‘very much worse’’) to +100% (‘‘very much bet-
ter’’).
Statistical analysis
Mean values and standard deviations (SD) or standard
errors ofmean (SEM)were computed for all parameters
and their absolute and relative changes after bronchodi-
lation. The nine baseline values as measured on the
33 study visits were compared to each other by re-
peated measures ANOVA performed in each group se-
parately (18). In an analogous manner the e¡ects of
medication, in terms of both absolute and per cent
changes, were compared to each other using mean va-
lues of the three repetitive tests.We included absolute
as well as per cent changes as both might be relevant in
patients with severe airway disease, depending on the
condition to be tested.
To account for the fact thatunder non-ideal conditions
there is no absolutely adequatemeasure of reproducibil-
ity and to facilitate the comparison with literature
data, two di¡erent measures of reproducibility were
computed. Firstly, variability of the three repetitive
measurements in terms of the coe⁄cient of variation
(SD/mean) was derived from the within-sum of squares
term in a repeated measures ANOVA of the changes
observed after each of the three study medications.
This variance re£ects the average residual variance
which can also be used for computing con¢dence
intervals or prediction intervals from SD values, as
needed. Despite their known weaknesses, coe⁄cients
of variationwere included to facilitate a comparisonwith
per cent changes that are often considered in practice
for clinical evaluation. Secondly, variability was ex-
pressed as intra-class correlation coe⁄cient which is a
measure of coincidence of repeated measurements that
takes into account correlation as well as di¡erences in
mean values (19). Statistical signi¢cancewas assumed for
Po0.05.
RESULTS
Baseline values
The median (range) interval to complete the study
was 13 (10^35) days. Patients with COPD and patients
570 RESPIRATORYMEDICINEwith asthma had similar age, weight and height (Table1).
Those with COPD had been smokers or were current
smokers, while none of those with asthma reported to
have ever smoked. IVC, FEV1%pred, FVC, FIV1, PIF, SRa-
win, SRawex,TLC, P0.1 and Pimax did not di¡er signi¢cantly
between groups (t-test,Table1), but FEV1in litres and PEF
were higher in asthma (Po0.05, each). Conversely, pa-
tients with COPD showed higher values of ITGV %pred
and of RV (Po0.05, each).TLCO was less (P=0.038) in pa-
tients with COPD compared to those with asthma. At
the time of the screening visit, sputum composition was
available in all patients studied by us. Sputum composi-
tion could be assessed in all patients; those with COPD
showed a median percentage of eosinophils of 1.2%, and
those with asthma a median of 4.2%. The levels of ex-
haled NO at a £ow rate of 50ml/s were 13 and 34ppb,
respectively.
Baseline values on each of the nine study visits did not
show signi¢cant di¡erences in theparametersmeasured.
In patients with COPD, 95%-ranges as derived from the
within-mean sum of squares were 7327ml for IVC,
7193ml for FEV1, 7368ml for FVC, and 7351ml for
FIV1. In patientswith asthma, the respective ranges wereTABLE 1. Patients’characteristics
Gender f/m
Age year
Height cm
Weight kg
Smokerex/current/never
Pack years
IVC l
FEV1 l
FEV1 %pred
FVC l
FIV1 l
PEF L s1
PIF L s1
SRawex cmH2O s
SRawin cmH2O s
TLC l
ITGV l
ITGV %pred
RV l
IC l
TLCO %pred
P0.1 kPa
Pimax kPa
For abbreviations see Methods. Mean values 7SD are given.
*P0.05.
**P 0.01.
***P 0.001.7424,7369,7547 and7456ml.Coe⁄cients of varia-
tion of baseline IVC, FVC, FEV1and FIV1were 4.2, 5.4, 6.1
and 5.0% in COPD and 3.7, 5.7, 6.3 and 4.9% in asthma,
respectively.
E¡ectsof fenoterol, oxitropiumbromide and
placebo
Patients with COPD
Mean values and mean intra-individual standard devia-
tions of the changes in lung function within repeated
tests are given inTable 2. Both in terms of absolute and
relative changes, IVC, FVC, FEV1, FIV1, PEF and PIF in-
creased signi¢cantly (Po0.01, each) after inhalation of fe-
noterol or oxitropiumbromide, as compared to placebo,
whereas SRawex, SRawin and P0.1 decreased (Po0.005,
each). In addition, oxitropium caused a signi¢cant change
in RV (Po0.005). TLC, ITGV, IC and Pimax did not change
signi¢cantly.
FIV1 in absolute terms increased by 301ml after feno-
terol and by 360ml after oxitropium, as compared to a
221ml increase in FEV1 after fenoterol (n.s., DFIV1 vs.COPD Asthma
3/10 3/7
6177 587 9
1727 6 1767 6
807 17 757 14
6/7/0 0/0/10
587 31 07 0***
3.397 0.64 3.827 0.40
1.567 0.45 2.037 0.39*
51.57 15.4 59.17 11.1
3.137 0.59 3.607 0.34
3.257 0.63 3.627 0.65
4.657 1.29 5.857 1.04*
5.517 1.30 5.197 1.38
34.47 17.0 23.77 14.9
18.87 8.8 18.87 8.1
7.147 0.98 6.827 1.08
4.807 0.80 4.547 1.74
144.77 20.3 117.47 23.8**
3.897 0.81 2.977 0.88*
2.297 0.41 2.697 0.60
62.87 19.6 85.37 10.9*
0.347 0.13 0.327 0.10
7.97 1.8 9.27 3.0
Level of signi¢cance of comparisons between groups (t-test).
TABLE 2A. Bronchodilator responses interms of changes in absolute values
COPD Asthma
Fenoterol Oxitropium Placebo Fenoterol Oxitropium Placebo
DIVC ml 3107138*** 4127144*** 547150 4977135*** 4457146*** 407161
DFVC ml 3397237*** 4157191*** 247125 5717170*** 4717179*** 57191
DFEV1 ml 221794
*** 235778*** 27758 6187162*** 4827121*** 267159
DFIV1 ml 3017135
*** 3607106*** 417100 5537228*** 4757109*** 587144
DPEF ml 5447389** 7477432*** 557395 16997673*** 13177901*** 487547
DPIF ml 1197424*** 2887489*** 2607614**** 9837709*** 8377625*** 2587549****
DTLC ml 757381 157187 417306 957244 1027339 747267
DITGV ml 1067259 2077237 647286 3837264*** 2557207* 727233
DRV ml 1917359 3877224*** 487286 4187270*** 3447319*** 487270
DIC ml 1817289 2217256 1037245 4777244** 3597329* 1497268
DSRawex cmH2O
.s 13.173.8*** 12.474.8*** 0.777.4 12.574.7*** 12.576.0*** 0.974.9
DSRawin cmH2O
.s 6.972.4*** 7.771.9*** 1.172.2 10.173.7*** 9.574.2*** 0.473.4
DP0.1 kPa 0.0870.08*** 0.0770.07*** 0.0170.07*** 0.0970.08*** 0.0870.06*** 0.0170.06
Pi max kPa 0.1770.65 0.2270.72 0.1278.5 0.0870.75 0.0270.66 0.0170.78
VAS 30.279.3*** 30.979.0*** 6.874.6 47.8710.1*** 45.777.4*** 7.979.6
Meanvalues andmean intra-individual standard deviations ofthe absolute changes in lung functionwithinrepeated tests are given.
*P**0.05, **P**0.01, ***P**0.005 as compared to placebo.Valuesmeasured after placebowere tested against zero using their 95% con¢dence intervals.
****P*o*0.05 as compared tozero.
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TABLE 2B Bronchodilator responses interms of changes inper cent values
COPD Asthma
Fenoterol Oxitropium Placebo Fenoterol Oxitropium Placebo
DIVC % 9.474.2*** 12.374.6*** 2.074.3 12.773.8*** 11.273.9*** 1.173.9
DFVC % 11.879.2*** 14.778.4*** 1.074.3 15.675.6*** 12.975.6*** 1.075.0
DFEV1 % 15.476.7
*** 15.476.5*** 1.974.5 30.479.2*** 23.876.1*** 1.377.4
DFIV1 % 9.574.5
*** 11.474.2*** 0.473.2 16.177.2*** 13.573.9*** 1.574.2
DPEF % 13.878.6*** 18.3710.3*** 0.879.6 33.2715.0*** 26.0715.5*** 0.779.8
DPIF % 3.478.7** 6.9710.5*** 5.1712.2**** 19.6717.5*** 16.7713.8*** 4.5710.8****
DTLC % 1.375.5 0.472.8 0.774.7 1.673.5 1.575.2 1.473.9
DITGV % 2.076.0 4.175.2 1.176.5 8.475.6*** 5.574.4* 1.375.0
DRV % 4.179.2 9.675.5*** 0.878.4 11.378.7*** 10.0710.5*** 2.779.7
DIC % 9.1714.8 11.0711.2 5.4710.6 17.4710.1* 12.6712.8 7.0713.0
DSRawex % 68.2716.8*** 63.4726.7*** 3.9740.5 64.6716.7*** 62.9728.3*** 6.6728.1
DSRawin % 35.679.2*** 39.977.5*** 4.579.6 53.178.7*** 48.2719.6*** 4.5721.1
DP0.1 % 23.6716.9*** 20.0719.5*** 0.9722.8 25.9725.7*** 25.6716.9*** 0.8733.3
Pimax % 2.178.9 3.0710.2 1.778.5 0.979.6 0.778.8 0.679.9
VAS 30.279.3*** 30.979.0*** 6.874.58 47.8710.1*** 45.777.4*** 7.979.6
Meanvalues andmean intra-individual standard deviations ofthe per centchanges in lung functionwithinrepeated tests are given.
*P 0.05, **P 0.01, ***P 0.005 as compared to placebo.Valuesmeasured after placebowere tested against zero using their 95% con¢dence intervals.
****Po0.05 as compared tozero.
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REPRODUCIBILITYOFFIV1 573DFEV1, paired t-test) and a 235ml increase after oxitro-
pium (P=0.021, DFIV1 vs. DFEV1). After placebo there
were no statistically signi¢cant changes, except in PIF
which decreased (Po0.05,Table 2).VAS scoreswerehigh-
er after fenoterol or oxitropium than after placebo
(Po0.005, each).
Patients with asthma
E¡ects were similar in terms of absolute and relative
changes. Both fenoterol and oxitropium bromide caused
a signi¢cant (Po0.05, each) increase in IVC, FVC, FEV1,
FIV1, PEF, PIF and IC (IC, only in terms of absolute values
after oxitropium) as compared to placebo, and a de-
crease in ITGV, RV, SRawex, SRawin and P0.1 (Po0.05,
each) (Tables 2A and B). No signi¢cant changes were
seen inTLC and Pimax.
The mean absolute changes in FIV1 after inhalation of
fenoterol or oxitropiumwere similar to the correspond-
ing changes in FEV1 (Tables 2A and B). Inhalation of place-
bo did not exert signi¢cant e¡ects on lung function,
except for a decrease in PIF (Po0.05). Mean VAS score
was signi¢cantly higher after fenoterol or oxitropium as
compared to placebo (Po0.005, each).
Reproducibility of lung function changes
Regarding FEV1, mean intra-individual variability was gi-
ven by coe⁄cients of variation of 33^43% after inhala-
tion of fenoterol or oxitropium in patients with COPDTABLE 3 Intra-class correlation coe⁄cients of bronchodilator
COPD
Fenoterol Oxitropium Plac
DIVC 0.77 0.57 0
DFVC 0.37 0.58 0
DFEV1 0.73 0.74 0
DFIV1 0.65 0.74 0
DPEF 0.78 0.69 0
DPIF 0.45 0.43 0
DTLC 0.28 0.45 0
DITGV 0.19 0.12 0
DRV 0.14 0.56 0
DIC 0.11 0.22 0
DSRawex 0.86 0.75 0
DSRawin 0.75 0.87 0
DP0.1 0.22 0.19 0
Pimax 0.04 0.01 0.
VAS 0.81 0.82 0
Values were derived from ANOVA tables of absolute chan
Methods.and of 25^31% in patients with asthma (cf.Tables 2A and
B).The respective range for FIV1was 29^47 and 23^41%.
Intra-class correlation coe⁄cients did notdi¡ermark-
edly between coe⁄cients referring to relative changes
and coe⁄cients referring to absolute changes (Table 3).
After placebo, values were always 0.6 and in many
cases close to zero. In contrast, after fenoterol or oxitro-
pium, intra-class correlation coe⁄cients were 0.6 re-
garding changes in FEV1, FIV1, SRawex, SRawin and
particularly VAS.
Correlation betweenVAS and lung function
parameters
To enable the comparisonwith our previous data (7), ad-
ditional correlation analyses were performed by re-
peated measures ANCOVA using the 33 absolute
changes and VAS as covariate.The analysis was done se-
parately in patients with more severe COPD (FEV1 50
%pred, n=7 (20)) and patients with less severe COPD
(FEV1 450 %pred, n=6). In severe COPD, there was
close relationship between the changes in dyspnoea and
the changes of FIV1 (P=0.004) butnot those of FEV1 (Fig.
1). In patients with less severe COPD, changes in dys-
pnoea were associated with changes in both FIV1
(P=0.005) and FEV1 (P=0.04). This ¢nding was similar
to that obtained in patients with asthma who
also showed a correlation between changes in VAS
and changes in FIV1 (P=0.001) as well as FEV1 (Po0.001)
(Fig.1).responses
Asthma
ebo Fenoterol Oxitropium Placebo
.38 0.85 0.87 0.10
.44 0.85 0.84 0.10
.53 0.73 0.81 0.13
.48 0.71 0.84 0.03
.15 0.44 0.40 0.08
.07 0.43 0.37 0.37
.03 0.02 0.39 0.20
.18 0.66 0.67 0.16
.11 0.71 0.49 0.03
.10 0.49 0.46 0.14
.35 0.78 0.77 0.49
.43 0.78 0.80 0.14
.05 0.15 0.34 0.19
30 0.35 0.37 0.12
.49 0.80 0.83 0.19
ges in three repeated measurements. For abbreviations see
FIG. 1. Relationship betweenVAS score and absolute changesin FIV1and FEV130min after inhalationof either fenoterol (K), oxitro-
piumbromide (~) or placebo (*) in patientswith severe COPD (panels A,D), less severe COPD (panels B,E), or asthma (panels C,
F).For abbreviations see Methods.
574 RESPIRATORYMEDICINEDISCUSSION
The present data demonstrate that changes in forced in-
spiratory volumes, after inhalation of a b2-agonist or an
anticholinergic, were similarly reproducible as changes in
forced expiratory volumes, both in patients with COPD
and in patients with asthma.Therefore, the assessment
of bronchodilator responses by inspiratory manoeuvres
appears not to su¡er from a lackof reproducibility.These
¢ndings support the assertion that forced inspiratory
manoeuvres provide valuable information in addition to
forced expiration, particularly in severe COPD.
In patients with COPD the absolute improvement in
FIV1 after bronchodilator inhalation was greater than
that in FEV1.When analysing the pattern of correlations
just as in a previous study (7), the subgroup of patients
withmore severe disease showeda closerelationshipbe-
tween the changes in dyspnoea and those in FIV1 (Fig.1A)
but not FEV1 (Fig. 1D). Irrespective of the small sample
size it seems noteworthy that this result is in agreement
with theprevious ¢ndingobtainedin amuch largergroup
(7).The fact that there was no such di¡erence when va-
lues were expressed as per cent changes frombaseline is
easily explainedby themuchhigher values of FIV1as com-pared to FEV1. We consider the correlation with dys-
pnoea which did not change when per cent changes
were taken for analysis (data not shown) as amajor argu-
ment for the assertion that the changes in FIV1arebetter
suited for the assessment of bronchodilation than those
in FEV1. In patients with less severe air£ow obstruction,
the relationship toVASwas similar for FEV1and FIV1 (Fig.
1B and E).The samewas true in asthma (Fig.1C and F), in
agreement with previous studies that showed a correla-
tion between symptoms and changes in FEV1in these pa-
tients (9,21,22). All of these ¢ndings are indicative of FIV1
being a close functional correlate of the sensation of dys-
pnoea both in asthma and COPD. As a prerequisite for
clinical application, the present study aimed to assess
the variability of FIV1 after bronchodilation in compari-
son to other, standard lung function parameters.
Bronchodilator responses aremost often quanti¢ed in
terms of the improvement in FEV1. In patients with se-
vere COPD, within-subject variability has been found to
be about two-thirds of the average bronchodilator re-
sponse, when measuring the e¡ect of inhalation of
250mg isoproterenol every 3 months over a 3-year peri-
od (10).Comparable values were reported regarding the
response to 400mg salbutamol over a 24-month period
REPRODUCIBILITYOFFIV1 575inpatientswithCOPDor asthma (11).Thereproducibility
of the changes in FEV1was lowest, when these were ex-
pressed relative to pre-bronchodilator (baseline) values,
coe⁄cients of variation being 50^61% in COPD and 34^
50% in asthma.Despite this, we referred to baseline va-
lues in the present study to achieve conformity with in-
ternationally established guidelines (23,24). In our data,
coe⁄cients of variation of FEV1 ranged between 33 and
43% in COPD, andbetween 25 and 30% in asthma (cf. Ta-
bles 2A and B).That these values were lower than those
reportedpreviously, ismost likelydue to the fact thatwe
measured over a shorter period of time.We also deter-
mined intra-class correlation coe⁄cients asmeasures of
reproducibility (19). Values were mostly above 0.6, ex-
ceeding even 0.8 in parameters such as VAS, and did not
di¡ermarkedly between FIV1and FEV1.
Although it was not the major aim of our study, we
also assessed the reproducibility of baseline lung func-
tion. The data available from the literature mainly refer
to repeated measurements of FEV1 and VC, some of
themwithin 20min (25). Based on such data, it was con-
cluded that in patients with mild to severe COPD im-
provements by 160ml for FEV1 and 330ml for VC were
required to con¢rm a positive bronchodilator response
with 95% con¢dence (25). Using the nine baseline mea-
surements we found 95%-ranges to be7327ml for IVC,
7193ml for FEV1, and7368ml for FVC in patients with
COPD. Probably these values were slightly larger than
the previous ones, because the interval of time between
tests was longer, itsmedian value being1.6 days.
Baseline values of forced inspiratory parameters have
been claimed to be as reproducible as those of forced ex-
piratory parameters (26), the conclusion being that FIV1
could equally well be used as FEV1. In the present study,
95%-ranges of baseline FIV1were7353ml in COPD and
7450ml in asthma. The respective per cent variability
was 5.1 and 4.9%. For comparison, the variability of
bronchodilator responses ranged from 29 to 45% and
from 23 to 41% (cf. Tables 2A and B), owing to the fact
that changes were much smaller than baseline values.
Most importantly, however, these values were similar
for FEV1, indicating that the measurement of both base-
line FIV1 and its change after bronchodilator inhalation
were as reproducible as the corresponding measure-
ments of FEV1.
Previous data on changes in FEV1and FVC showed no
signi¢cant e¡ects after administration of placebo (27).
Our data were in accordance with that (Tables 2A and
B), except for a slight reduction in PIF in both groups.
We do not have an explanation for this. It is unlikely that
a reduction inmaximum e¡ort was the cause, since Pimax
did not change. Also, the changes in RV were probably
too small to result in signi¢cant changes in Pimax. Note-
worthy is fact that, in our previous study on bronchodi-
lator responses inpatientswith, on average,more severe
COPD, changes of PIF always paralleled those of FIV1 (7).The ¢ndings that Pimax was not altered after bronchodila-
tor inhalation and that the correlation between changes
in dyspnoea and FIV1was best in themore severely ill pa-
tients, indicate that the correlation with forced inspira-
tion was not based on changes in respiratory e¡ort or
maximumcapabilitybutre£ected the changes in bronch-
omotor tone that were unmasked during forced inspira-
tion.
It has oftenbeen suspected that FEV1mightnotbe the
most suitable parameter to assess bronchodilation in
COPD. Alternative measures that have been proposed
include FRC, IC and FIV1 during rest (28), as well as IC
during exercise (29,30). Although IC and FRC are sensi-
tive markers of bronchodilation in the presence of ex-
piratory £ow limitation (31), we did not observe
signi¢cant changes, probably because patients showed a
less severe disease than those included in previous stu-
dies. The only parameter related to lung hyperin£ation
that showed a signi¢cant change was RVafter inhalation
of oxitropium. In contrast to COPD, patients with asth-
ma demonstrated statistically signi¢cant e¡ects in IC,
ITGVand RV (Tables 2A and B).TLC showed no change,
thereby underlining the validity of volume measure-
ments.
It appears that inpatientswithCOPDdi¡erent indices
of bronchodilation have di¡erent magnitudes and show
di¡erent sensitivity with regard to dyspnoea, depending
on the severity of the disease (Figs.1A, B, D and E). Ac-
cordingly, it seems not possible to distinguish between
asthma and COPD solely by judging from short-term
bronchodilator responses (32) (Figs.1B,C, E and F). Posi-
tive bronchodilator responses in COPD were found to
be linked to the presence of eosinophilia and bronchiolar
¢brosis, and negative responses to goblet cellmetaplasia
and emphysema (33). In addition, patients with COPD,
who showedpartial reversibility, exhibitedmore sputum
eosinophils and higher levels of exhaled NO than pa-
tients without reversibility (34). In the present study all
patientswithCOPD showed a lowpercentage of eosino-
phils and low levels of exhaledNO (35),whereas patients
with asthma demonstrated higher values in both, con-
¢rming the diagnosis of COPD vs. asthma (36,37).
According to previous studies, b2-agonists and antic-
holinergics can be considered as similarly e¡ective with
regard to changes in FEV1 in patients with COPD
(38,39). Moreover, for the doses used by us, i.e. 200mg
of either fenoterol or oxitropium bromide, equi-e¡ec-
tiveness is to be assumed (38). Accordingly, we did not
¢nd signi¢cant di¡erences between the two drugs in
COPD, neither in terms of expiratory nor in terms of in-
spiratory parameters. Patients with asthma, however,
showed a tendency towards greater e¡ects of fenoterol
as compared to oxitropium, in agreement with previous
results (40).
In summary, our study demonstrated that bronchodi-
lator responses to fenoterol or oxitropium bromide in
576 RESPIRATORYMEDICINEpatients with COPD or asthma had similar reproducibil-
ity, when quanti¢ed in terms of FIV1vs. FEV1, particularly
as per cent changes. In patients with severe COPD, dys-
pnoea was related to FIV1only, whereas in patients with
less severe COPD or asthma it was related to both FIV1
and FEV1.These ¢ndings suggest that the assessment of
bronchodilation through FIV1is a reproducible and infor-
mative procedure, particularly in severe COPD.
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